Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the recurrent or metastatic nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
DRUG: Gemcitabine combined with Aptinib and Toripalimab
Adverse events, The safety will be assessed by ongoing reviews of clinical laboratory tests, Eastern Cooperative Oncology Group (ECOG) performance status, physical examination, electrocardiogram (ECG), and adverse events. Evaluations of immune safety will also be conducted (immune-related adverse events (AEs), or labs of autoimmune sera, inflammatory events, and immunogenicity). Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study., 12months
The proportion of patients who achieved an objective response, Defined as those with radiologically confirmed complete or partial response according to RECIST 1.1 assessed by the investigator;, 12 months|The proportion of patients who achieved disease control,, Defined as those with RECIST-defined objective response or stable disease;, 12months|The proportion of patients who achieved clinical benefit, Defined as those with confirmed objective response or stable disease that lasted for at least 6 months;, 12 months|Progression-free survival (median and at 6 and 12 months), Defined from the enrolment to RECISTdefined progression or death from any causes;, 12 months|Duration of response, Defined as the time from first documentation of objective response to radiological disease progression., 12 months
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the recurrent or metastatic nasopharyngeal carcinoma.

Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.Tumor response will be assessed by radiographic examination in screening visit and every 2 cycles after first dose.